Drug Approval | June 12, 2022
Alembic receives USFDA tentative approval for Dasatinib tablets
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Subscribe To Our Newsletter & Stay Updated
